Advertisement

Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy

  • Maria Lorenzi
  • Baishali Ambegaonkar
  • Carl A. Baxter
  • Jeroen Jansen
  • Michael J. Zoratti
  • Glenn Davies
Original Paper
  • 42 Downloads

Abstract

Purpose

While statins are used as first-line treatments for high-risk patients with hypercholesterolemia, statin monotherapy is often insufficient to achieve target low-density lipoprotein cholesterol (LDL-C) levels. Second-line treatment options include up-titration of statin dose, switching to a more potent statin, or combination therapy, e.g., with ezetimibe. The aim of this study was to evaluate the efficacy of adding ezetimibe to simvastatin, atorvastatin, or rosuvastatin monotherapy versus doubling the dosage or switching to a higher-potency statin in a population of patients with hypocholesterolemia at high risk of cardiovascular disease (CVD) and who had been previously treated with a statin.

Methods

A systematic literature search was performed and evidence bases were established for populations of atorvastatin-, simvastatin-, and rosuvastatin-experienced patients using eligible randomized controlled trials (RCTs). Based on the available data, we constructed networks of evidence and conducted a Bayesian network meta-analysis (NMA) within each statin population. The primary outcome of interest was percent change from baseline in LDL-C. Changes in total cholesterol were explored as a secondary outcome.

Findings

Across all patient populations, 35 RCTs were identified and included in the evidence base. Among patients on simvastatin therapy, the addition of ezetimibe resulted in a mean difference (MD) in LDL-C of − 13.62% (95% CrI − 19.99, − 6.91; see table below) compared to doubling the starting dose of simvastatin. In the population of patients on atorvastatin therapy, the addition of ezetimibe resulted in an MD in LDL-C of − 14.71% (95% CrI − 16.46, − 12.95) compared to doubling the starting dose of atorvastatin. The addition of ezetimibe to rosuvastatin resulted in an MD in LDL-C of − 14.96% (95% CrI − 17.79, − 12.11), compared to doubling the starting rosuvastatin dose. Similar trends were observed for changes in total cholesterol.

Implications

Given the available data, the addition of ezetimibe to ongoing simvastatin, atorvastatin, or rosuvastatin monotherapy offers greater reduction in LDL-C among patients at high risk of CVD compared to doubling the initial statin dose.

Keywords

Network meta-analysis Cholesterol Statins Ezetimibe 

References

  1. 1.
    Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atheroscleroticcardiovascular risk in adults: a report of the American College of Cardiology/American Heart AssociationTask Force on Practice Guidelines. J Am Coll Cardiol 63:2889–934CrossRefGoogle Scholar
  2. 2.
    Reiner Z, Catapano A, De Backer G et al (2011) ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 32:1769–1818CrossRefGoogle Scholar
  3. 3.
    Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) CA, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Perrone Filardi P, Riccardi G, Storey RF, Wood D; ESC Committee for Practice Guidelines 2008–2010 and 2010–2012 Committees (2011) ESC/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 217(Suppl 1):S1–S44Google Scholar
  4. 4.
    Jellinger PSSD, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, Shepherd MD, Seibel JA (2012) AACE task force for management of dyslipidemia and prevention of atherosclerosis. American Association of Clinical Endocrinologists’ Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract 18(Suppl 1):1–78CrossRefGoogle Scholar
  5. 5.
    Go ASMD, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB, American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2013) Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation 127:e6–e245Google Scholar
  6. 6.
    Chaudhary R, Garg J, Shah N, Sumner A (2017) PCSK9 inhibitors: a new era of lipid lowering therapy. World J Cardiol 9(2):76–91CrossRefGoogle Scholar
  7. 7.
    Di Bartolo B, Scherer DJ, Brown A, Psaltis PJ, Nicholls SJ (2017) PCSK9 inhibitors in hyperlipidemia: current status and clinical outlook. BioDrugs: Clin Immunother Biopharm Gene Ther 31(3):167–174CrossRefGoogle Scholar
  8. 8.
    Fox KM, Tai MH, Kostev K, Hatz M, Qian Y, Laufs U (2018) Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol 107(5):380–388CrossRefGoogle Scholar
  9. 9.
    Laufs U, Karmann B, Pittrow D (2016) Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk. Clin Res Cardiol 105(9):783–790CrossRefGoogle Scholar
  10. 10.
    Soran H, Dent R, Durrington P (2017) Evidence-based goals in LDL-C reduction. Clin Res Cardiol 106(4):237–248CrossRefGoogle Scholar
  11. 11.
    Wada H, Dohi T, Miyauchi K et al (2017) Prognostic impact of nutritional status assessed by the controlling nutritional status score in patients with stable coronary artery disease undergoing percutaneous coronary intervention. Clin Res Cardiol 106(11):875–883CrossRefGoogle Scholar
  12. 12.
    Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL (2007) Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 23(8):2009–2026CrossRefGoogle Scholar
  13. 13.
    Mikhailidis DP, Lawson RW, McCormick A et al (2011) Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Curr Med Res Opin 27(6):1191–1210CrossRefGoogle Scholar
  14. 14.
    Morrone D, Weintraub WS, Toth PP et al (2012) Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Artherosclerosis 223:11CrossRefGoogle Scholar
  15. 15.
    National Clinical Guideline Centre (2014) Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. NICE guideline CG181. National Clinical Guideline Centre, LondonGoogle Scholar
  16. 16.
    Lu G, Ades AE (2004) Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 23(20):3105–3124CrossRefGoogle Scholar
  17. 17.
    Bucher HC, Guyatt GH, Griffith LE, Walter SD (1997) The results of direct and indirect treatmentcomparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50:683–691CrossRefGoogle Scholar
  18. 18.
    Spiegelhalter DJ, Abrams KR, Myles JP (2004) Bayesian approaches to clinical trials and health-care evaluation. Wiley, ChichesterGoogle Scholar
  19. 19.
    Averna M, Zaninelli A, Le Grazie C, Gensini GF (2010) Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients. J Clin Lipidol 4(4):272–278CrossRefGoogle Scholar
  20. 20.
    Ballantyne CM, Bertolami M, Hernandez Garcia HR et al (2006) Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am Heart J 151(5):975.e971–975.e979CrossRefGoogle Scholar
  21. 21.
    Bardini G, Giorda CB, Pontiroli AE, Le Grazie C, Rotella CM (2010) Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). Cardiovasc Diabetol 9:20CrossRefGoogle Scholar
  22. 22.
    Brohet C, Banai S, Alings AM, Massaad R, Davies MJ, Allen C (2005) LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. Curr Med Res Opin 21(4):571–578CrossRefGoogle Scholar
  23. 23.
    McCormack T, Harvey P, Gaunt R et al (2010) Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets. Int J Clin Pract 64(8):1052–1061CrossRefGoogle Scholar
  24. 24.
    Mulder DJ, van Haelst PL, Wobbes MH et al (2007) The effect of aggressive versus conventional lipid-lowering therapy on markers of inflammatory and oxidative stress. Cardiovasc Drugs Ther 21(2):91–97CrossRefGoogle Scholar
  25. 25.
    Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J (2005) A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 80(5):587–595CrossRefGoogle Scholar
  26. 26.
    Pesaro AE, Serrano CV Jr, Fernandes JL et al (2012) Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin. Int J Cardiol 158(3):400–404CrossRefGoogle Scholar
  27. 27.
    Rosen JB, Jimenez JG, Pirags V et al (2013) A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease. Diabetes Vasc Disease Res 10(3):277–286CrossRefGoogle Scholar
  28. 28.
    Ruggenenti P, Cattaneo D, Rota S et al (2010) Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial. Diabetes Care 33(9):1954–1956CrossRefGoogle Scholar
  29. 29.
    Schuster H, Barter PJ, Stender S et al (2004) Effects of switching statins on achievement of lipid goals: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study. Am Heart J 147(4):705–713CrossRefGoogle Scholar
  30. 30.
    Van Dam M, Basart DCG, Janus C et al (2000) Additional efficacy of milligram-equivalent doses of atorvastatin over simvastatin. Clin Drug Investig 19(5):327–334CrossRefGoogle Scholar
  31. 31.
    Zubaid M, Shakir DK, Bazargani N et al (2008) Effect of ezetimibe coadministration with simvastatin in a Middle Eastern population: a prospective, multicentre, randomized, double-blind, placebo-controlled trial. J Cardiovasc Med 9(7):688–693CrossRefGoogle Scholar
  32. 32.
    Barbosa SP, Lins LC, Fonseca FA et al (2013) Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein. Life Sci 92(14–16):845–851CrossRefGoogle Scholar
  33. 33.
    Barrios V, Amabile N, Paganelli F et al (2005) Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Int J Clin Pract 59(12):1377–1386CrossRefGoogle Scholar
  34. 34.
    Bays HE, Averna M, Majul C et al (2013) Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia. Am J Cardiol 112(12):1885–1895CrossRefGoogle Scholar
  35. 35.
    Conard SE, Bays HE, Leiter LA et al (2008) Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart diseaseconflicts of interest. Am J Cardiol 102(11):1489–1494CrossRefGoogle Scholar
  36. 36.
    Constance C, Westphal S, Chung N et al (2007) Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus. Diabetes Obes Metabol 9(4):575–584CrossRefGoogle Scholar
  37. 37.
    Cruz-Fernandez JM, Bedarida GV, Adgey J, Allen C, Johnson-Levonas AO, Massaad R (2005) Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. Int J Clin Pract 59(6):619–627CrossRefGoogle Scholar
  38. 38.
    Hing Ling P, Civeira F, Dan A et al. (2012) Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study. Lipids in Health Dis 11:18CrossRefGoogle Scholar
  39. 39.
    Kurabayashi M, Yamazaki T, Group SS (2008) Superior benefit of aggressive lipid-lowering therapy for high-risk patients using statins: the SUBARU study–more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy. J Atheroscler Thromb 15(6):314–323CrossRefGoogle Scholar
  40. 40.
    Leiter LA, Bays H, Conard S et al (2008) Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol 102(11):1495–1501CrossRefGoogle Scholar
  41. 41.
    Matsue Y, Matsumura A, Suzuki M, Hashimoto Y, Yoshida M (2013) Differences in action of atorvastatin and ezetimibe in lowering low-density lipoprotein cholesterol and effect on endothelial function: randomized controlled trial. Circ J 77(7):1791–1798CrossRefGoogle Scholar
  42. 42.
    Okada K, Kimura K, Iwahashi N et al (2011) Clinical usefulness of additional treatment with ezetimibe in patients with coronary artery disease on statin therapy. From the viewpoint of cholesterol metabolism. Circ J 75(10):2496–2504CrossRefGoogle Scholar
  43. 43.
    Padhy BM, Yadav R, Gupta YK (2013) Hypolipidaemic and anti-inflammatory effects of fixed dose combination of atorvastatin plus ezetimibe in Indian patients with dyslipidaemia. Singap Med J 54(2):90–95CrossRefGoogle Scholar
  44. 44.
    Stein E, Stender S, Mata P et al (2004) Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 148(3):447–455CrossRefGoogle Scholar
  45. 45.
    Zieve F, Wenger NK, Ben-Yehuda O et al (2010) Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients> or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study). Am J Cardiol 105(5):656–663CrossRefGoogle Scholar
  46. 46.
    Bays HE, Davidson MH, Massaad R et al (2011) Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am J Cardiol 108(4):523–530CrossRefGoogle Scholar
  47. 47.
    Torimoto K, Okada Y, Mori H et al. Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes. Lipids Health Dis 2013;12(1)CrossRefGoogle Scholar
  48. 48.
    Yamazaki D, Ishida M, Watanabe H et al (2013) Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe. Lipids Health Dis 12:9CrossRefGoogle Scholar
  49. 49.
    Leitersdorf E (2001) Cholesterol absorption inhibition: filling an unmet need in lipid-lowering management. Eur Heart J Suppl 3(suppl E):E17–E23CrossRefGoogle Scholar
  50. 50.
    Baigent C, Blackwell L, Emberson J et al (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753):1670–1681CrossRefGoogle Scholar
  51. 51.
    Ambegaonkar BM, Tipping D, Polis AB, Tomassini JE, Tershakovec AM (2014) Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis. Atherosclerosis 237(2):829–837CrossRefGoogle Scholar
  52. 52.
    Cannon CP, Giugliano MAB (2015) RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372(25):2387–2397CrossRefGoogle Scholar
  53. 53.
    Lloyd-Jones DM, Morris PB, Ballantyne CM et al (2016) 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 68:92–125CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Precision Health EconomicsOaklandUSA
  2. 2.Merck & Co., Inc.KenilworthUSA
  3. 3.MSD LtdHoddesdonUK

Personalised recommendations